A pilot study comparing basiliximab and anti-thymocyte globulin as induction therapy in sensitized renal allograft recipients.
Mariat
C
C
Service de Néphrologie Dialyse Transplantation Rénale Hôpital Nord, CHU de Saint-Etienne, France.
Afiani
A
A
Alamartine
E
E
Thibaudin
D
D
de Filippis
J P
JP
Berthoux
F
F
D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D000077552:Basiliximab; D003586:Cytomegalovirus Infections / Q000453:epidemiology; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology* / Q000379:methods; D010865:Pilot Projects; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology; D011993:Recombinant Fusion Proteins
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab